¼¼°èÀÇ ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ½ÃÀå
Bionic Eyes
»óǰÄÚµå : 1785844
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 286 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ½ÃÀåÀº 2030³â±îÁö 6¾ï 5,710¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 3¾ï 2,720¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 12.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 6¾ï 5,710¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿Ü¾ÈºÎ´Â CAGR 11.5%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 4¾ï 2,290¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Implanted Eye ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 13.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8,910¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR16.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ½ÃÀåÀº 2024³â¿¡´Â 8,910¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 3,690¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 16.4%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 9.1%¿Í 10.9%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.7%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

±â¼ú Çõ½ÅÀÌ ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ½ÃÀåÀ» ¾î¶»°Ô ÀçÁ¤ÀÇÇϰí Àִ°¡?

¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ºÐ¾ß´Â ½Å°æº¸Ã¶, ÀΰøÁö´É, ¹ÙÀÌ¿À ÀÏ·ºÆ®·Î´Ð½ºÀÇ ÃÖ÷´Ü ±â¼úÀ» ÅëÇØ ±Þ¼ÓÇÑ ¹ßÀüÀ» °ÅµìÇϰí ÀÖ½À´Ï´Ù. °úÇÐÀÚµé°ú ¿¬±¸ÀÚµéÀº °íÇØ»óµµ ¸Á¸· À̽Ä, ±¤À¯ÀüÇп¡ ±â¹ÝÇÑ ½Ã·Â ȸº¹, ¹«¼± ½Ã°¢ º¸Ã¶À» °³¹ßÇÏ¿© ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁîÀÇ ±â´ÉÀ» Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. AI ±â¹Ý À̹ÌÁö ó¸®ÀÇ ÅëÇÕÀ» ÅëÇØ ÀÌ·¯ÇÑ ÀÓÇöõÆ®´Â ½Ã°¢ µ¥ÀÌÅ͸¦ º¸´Ù È¿°úÀûÀ¸·Î ÇØ¼®ÇÏ¿© »ç¿ëÀÚ¿¡°Ô º¸´Ù ¼±¸íÇϰí ÀûÀÀ·ÂÀÌ ³ôÀº ½Ã°¢ ±â´ÉÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ºÎǰÀÇ ¼ÒÇüÈ­¿Í »ýü ÀûÇÕ¼º Àç·áÀÇ »ç¿ëÀ¸·Î ÀÓÇöõÆ®ÀÇ ¼ö¸í°ú Æí¾ÈÇÔÀÌ Çâ»óµÇ¾î, ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî´Â ÅðÇ༺ ¾ÈÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷µé¿¡°Ô Àå±âÀûÀ¸·Î ½ÇÇà °¡´ÉÇÑ ¼Ö·ç¼ÇÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ú-ÄÄÇ»ÅÍ ÀÎÅÍÆäÀ̽º(BCI) ±â¼úÀÇ ¹ß´Þ·Î ½Ã°¢ ¿µ¿ªÀ» Á÷Á¢ ÀÚ±ØÇÒ ¼ö ÀÖ´Â ±æÀÌ ¿­¸®°í ÀÖÀ¸¸ç, ½Ã½Å°æÀÌ ¼Õ»óµÈ °æ¿ì¿¡µµ ½Ã·ÂÀ» ȸº¹ÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¿¬±¸°¡ ÁøÇàµÊ¿¡ µû¶ó ¾÷°è´Â ±âÁ¸ÀÇ Ä«¸Þ¶ó ±â¹Ý ÀÓÇöõÆ®¿¡¼­ ½Ç½Ã°£ ȯ°æ ÀûÀÀÀÌ °¡´ÉÇÑ º¸´Ù Áøº¸µÈ ¼Ö·ç¼ÇÀ¸·ÎÀÇ ÀüȯÀ» ¸ñ°ÝÇϰí ÀÖÀ¸¸ç, ½Ã·Â ȸº¹¿¡ º¯È­¸¦ °¡Á®¿Ã ¼ö ÀÖ´Â ¹«´ë°¡ ¸¶·ÃµÇ°í ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî¿¡ ´ëÇÑ ¼ö¿ä°¡ Àα¸Åë°èÇÐÀûÀ¸·Î Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

¼¼°èÀûÀ¸·Î ½Ã°¢ Àå¾ÖÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, 2¾ï 8,500¸¸ ¸í ÀÌ»óÀÇ »ç¶÷µéÀÌ ½Ã·Â ÀúÇÏ·Î °íÅë¹Þ°í ÀÖÀ¸¸ç, ³ëÈ­¼º Ȳ¹Ýº¯¼º(AMD), ´ç´¢¸Á¸·º´Áõ, ¸Á¸·»ö¼Òº¯¼ºÁõÀÌ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ­, ƯÈ÷ ¼±Áø±¹¿¡¼­´Â ÷´Ü ½Ã·Â ȸº¹ ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ ³ô¾ÆÁö¸é¼­ ¹ÙÀÌ¿À´Ð ¾È±¸ ÀÓÇöõÆ®ÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ´ç´¢º´À¸·Î ÀÎÇÑ ½Ã·ÂÀúÇÏ¿Í ¼±Ãµ¼º ¾ÈÁúȯ »ç·Ê°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¹üÀ§¸¦ ´õ¿í È®´ë½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Ã·Â ȸº¹ ÀåÄ¡¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»óÀ» À§ÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ÇコÄɾî Á¤Ã¥¿¡ ÈûÀÔ¾î º¸Á¶ ÀÇ·á ±â¼ú¿¡ ´ëÇÑ Àνİú ¼ö¿ëµµ°¡ ³ô¾ÆÁø °Íµµ ÀÌ ¼ö¿ä¿¡ ±â¿©ÇÏ´Â ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¾È°ú ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í ÀÇ·áºñ Áõ°¡¿¡ µû¶ó ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ¼Ö·ç¼ÇÀº ½ÇÇèÀûÀÎ Á¦Ç°¿¡¼­ Á¡Â÷ ½Ç¿ëÈ­ °¡´ÉÇÑ Á¦Ç°À¸·Î ÀüȯµÇ°í ÀÖÀ¸¸ç, Àü ¼¼°è ¼ö¹é¸¸ ¸íÀÇ ½Ã°¢ Àå¾ÖÀÎÀÇ »îÀ» º¯È­½Ãų ¼ö ÀÖ´Â ÇýÅÃÀ» ±â´ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä »ê¾÷ ±â¾÷¿Í Àü·«Àû ÅõÀÚ´Â ¾î¶»°Ô ½ÃÀåÀ» Çü¼ºÇϰí Àִ°¡?

°æÀï ȯ°æÀº ¿¬±¸°³¹ß(R&:D), Àü·«Àû ÆÄÆ®³Ê½Ê, °øµ¿ Çõ½Å¿¡ ÁßÁ¡À» µÎ°í ÀÖ´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. Second Sight Medical Products, Pixium Vision, Bionic Vision Technologies µî ÁÖ¿ä ±â¾÷µéÀº Â÷¼¼´ë ½Ã°¢ º¸Á¶±â±¸ °³¹ßÀÇ ÃÖÀü¼±¿¡ ¼­ ÀÖ½À´Ï´Ù. ³ª³ë ±â¼ú, ¹«¼± Àü·Â Àü¼Û, Ŭ¶ó¿ìµå ±â¹Ý µ¥ÀÌÅÍ Ã³¸®¸¦ ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ½Ã½ºÅÛ¿¡ ÅëÇÕÇÔÀ¸·Î½á ÀåºñÀÇ È¿À²¼ºÀÌ Çâ»óµÇ°í, ½ÃÀå È®´ëÀÇ »õ·Î¿î ±âȸ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ±â°ü, ÇÏÀÌÅ×Å© ±â¾÷, ´ëÇÐ °£ÀÇ Çù·ÂÀº ±â¼ú Çõ½ÅÀÇ ¼Óµµ¸¦ °¡¼ÓÈ­ÇÏ¿© º¸´Ù Á¤±³ÇÑ ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ¼Ö·ç¼ÇÀÇ »ó¿ëÈ­¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ ÁøÈ­ÇÔ¿¡ µû¶ó ±â¾÷µéÀº ¹Ì±¹ FDA, À¯·´ÀǾàǰû(EMA) µî ±ÔÁ¦±â°üÀÇ ½ÂÀÎÀ» ¹Þ±â À§ÇØ ÀÓ»ó½ÃÇè¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. º¥Ã³ ijÇÇÅ» ±â¾÷°ú Á¤ºÎ ÀÚ±ÝÀÌ ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê¸¦ °­È­ÇÔ¿¡ µû¶ó ¾÷°è´Â Á¡Á¡ ´õ È¿°úÀûÀÌ°í ³Î¸® ÀÌ¿ë °¡´ÉÇÑ ½Ã·Â ȸº¹ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ±Ëµµ¿¡ ¿À¸£°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇコÄÉ¾î ºÐ¾ß¿¡¼­ AI¿Í ·Îº¿°øÇÐÀÇ ¿µÇâ·ÂÀÌ Ä¿Áö¸é¼­ ȯÀÚ °æÇèÀ» ÀçÁ¤ÀÇÇÏ°í ¹ÙÀÌ¿À´Ð¾ÆÀÌ ±â¼úÀÇ Æø³ÐÀº ¼ö¿ë°ú äÅÃÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÈ­ÇÏ´Â ÁÖ¿ä ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ½Ã·Â °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡, ¾È°ú ºÐ¾ß¿¡¼­ÀÇ Àû¿ë È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. »ýü°øÇÐ ¸Á¸· À̽Ä, ±¤ÀüÀÚ ÀåÄ¡, ½Å°æ ÀÎÅÍÆäÀ̽ºÀÇ È¹±âÀûÀÎ ¹ßÀüÀ¸·Î ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁîÀÇ È¿´ÉÀÌ Å©°Ô Çâ»óµÇ¾î ½Ã·Â ȸº¹À» À§ÇÑ À¯·ÂÇÑ ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. °í·ÉÈ­ »çȸ¿Í ´õºÒ¾î Àü ¼¼°èÀûÀ¸·Î ¾ÈÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÷´Ü Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁî ±â¼úÀº ½Ã°¢ Àå¾Ö¿¡ ´ëÇÑ Áß¿äÇÑ ¼Ö·ç¼ÇÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤ºÎ º¸Á¶±Ý°ú º¸Çè Àû¿ëÀ¸·Î À̽ÄÇü ÀÇ·á±â±âÀÇ °¡°ÝÀÌ Àú·ÅÇØÁ® ¼±Áø±¹°ú ½ÅÈï °æÁ¦±¹ ¸ðµÎ¿¡¼­ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¼ÒºñÀÚ Çൿµµ ÁøÈ­Çϰí ÀÖÀ¸¸ç, ¿þ¾î·¯ºí ¹× ÀÓº£µðµå º¸Á¶ ±â¼ú¿¡ ´ëÇÑ ¼ö¿ëÀÌ È®´ëµÇ¸é¼­ ½ÃÀå Æ®·»µå°¡ ÀçÆíµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI ±â¹Ý ½Ã°¢ °­È­ µµ±¸¿Í Áõ°­Çö½Ç(AR) ÅëÇÕ¿¡ ´ëÇÑ Àü·«Àû ÅõÀÚ´Â ÁßÁõ ½Ã·Â »ó½Ç ȯÀڵ鿡°Ô »õ·Î¿î °¡´É¼ºÀ» Á¦½ÃÇÏ¸ç ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ¾÷°è°¡ ȯÀÚ Áß½ÉÀÇ Çõ½ÅÀ¸·Î ³ª¾Æ°¡°í ÀÖ´Â °¡¿îµ¥, »ý¸í°øÇÐ, µðÁöÅÐ Çコ, Á¤¹ÐÀÇ·áÀÇ À¶ÇÕÀº Àü ¼¼°èÀûÀ¸·Î ¹ÙÀÌ¿À´Ð ¾ÆÀÌÁîÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­ÇÒ °ÍÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(¿Ü¾ÈºÎ, À̽ÄÇü ¾È±¸);ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ÃÖÁ¾»ç¿ëÀÚ, ¿Ü·¡½Ã¼³ ÃÖÁ¾»ç¿ëÀÚ, ¿¬±¸ ¹× Á¦Á¶ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå°ú °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Bionic Eyes Market to Reach US$657.1 Million by 2030

The global market for Bionic Eyes estimated at US$327.2 Million in the year 2024, is expected to reach US$657.1 Million by 2030, growing at a CAGR of 12.3% over the analysis period 2024-2030. External Eye, one of the segments analyzed in the report, is expected to record a 11.5% CAGR and reach US$422.9 Million by the end of the analysis period. Growth in the Implanted Eye segment is estimated at 13.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$89.1 Million While China is Forecast to Grow at 16.4% CAGR

The Bionic Eyes market in the U.S. is estimated at US$89.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$136.9 Million by the year 2030 trailing a CAGR of 16.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 10.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.

Global Bionic Eyes Market - Key Trends & Drivers Summarized

How Are Technological Breakthroughs Redefining the Bionic Eyes Market?

The field of bionic eyes is experiencing rapid advancements driven by cutting-edge technologies in neuroprosthetics, artificial intelligence, and bioelectronics. Scientists and researchers are developing high-resolution retinal implants, optogenetics-based vision restoration, and wireless visual prosthetics, significantly enhancing the functionality of bionic eyes. The integration of AI-powered image processing allows these implants to interpret visual data more effectively, providing users with sharper, clearer, and more adaptive vision capabilities. Miniaturization of components and the use of biocompatible materials have improved implant longevity and comfort, making bionic eyes a viable long-term solution for individuals suffering from degenerative eye conditions. Moreover, developments in brain-computer interface (BCI) technology are paving the way for direct visual cortex stimulation, which has the potential to restore vision even in cases where optic nerve damage has occurred. As research progresses, the industry is witnessing a shift from traditional camera-based implants to more advanced solutions capable of real-time environmental adaptation, setting the stage for a transformative impact in vision restoration.

Why Is the Demand for Bionic Eyes Rising Across Demographics?

The increasing prevalence of visual impairments worldwide is a crucial factor driving the demand for bionic eyes. According to the World Health Organization (WHO), over 285 million people suffer from vision loss, with a significant proportion affected by age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa. The aging global population, particularly in developed nations, has fueled the need for advanced vision restoration solutions, leading to greater adoption of bionic eye implants. In parallel, rising cases of diabetes-induced vision loss and congenital eye disorders have further expanded the market scope. Another factor contributing to this demand is the growing awareness and acceptance of assistive medical technologies, supported by government initiatives and healthcare policies aimed at improving accessibility to vision restoration devices. With increased investments in ophthalmology research and higher healthcare expenditure, bionic eye solutions are gradually transitioning from experimental to commercially viable products, promising life-changing benefits for millions of visually impaired individuals worldwide.

How Are Key Industry Players and Strategic Investments Shaping the Market?

The competitive landscape of the bionic eyes market is marked by a strong emphasis on research and development (R&D), strategic partnerships, and collaborative innovations. Leading companies such as Second Sight Medical Products, Pixium Vision, and Bionic Vision Technologies are at the forefront of developing next-generation visual prosthetics. The integration of nanotechnology, wireless power transmission, and cloud-based data processing in bionic eye systems has enhanced device efficiency, opening new opportunities for market expansion. Additionally, collaboration between medical institutions, tech firms, and universities has accelerated the pace of innovation, leading to the commercialization of more sophisticated bionic eye solutions. As regulatory frameworks evolve, companies are investing heavily in clinical trials to secure approvals from regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA). With venture capital firms and government funding bolstering research initiatives, the industry is on track to deliver increasingly effective and widely accessible vision restoration solutions. Moreover, the growing influence of AI and robotics in the healthcare sector is expected to redefine patient experiences, driving broader acceptance and adoption of bionic eye technology.

What Are the Key Drivers Accelerating the Growth of the Bionic Eyes Market?

The growth in the bionic eyes market is driven by several factors, including technological advancements, increasing prevalence of vision-related disorders, and expanding applications in ophthalmology. Breakthroughs in bioengineered retinal implants, optoelectronic devices, and neural interfacing have significantly improved the efficacy of bionic eyes, making them a compelling option for vision restoration. The rising global burden of eye diseases, coupled with the aging population, has intensified demand for advanced treatment options, positioning bionic eye technology as a crucial solution for visual impairments. Additionally, the increasing affordability of implantable medical devices, aided by government subsidies and insurance coverage, has facilitated greater accessibility in both developed and emerging economies. Consumer behavior is also evolving, with growing acceptance of wearable and implantable assistive technologies reshaping market trends. Furthermore, strategic investments in AI-driven visual enhancement tools and augmented reality (AR) integration are propelling the market forward, offering new possibilities for patients with severe vision loss. As the industry moves toward more patient-centric innovations, the convergence of biotechnology, digital health, and precision medicine will continue to accelerate the adoption of bionic eyes on a global scale.

SCOPE OF STUDY:

The report analyzes the Bionic Eyes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (External Eye, Implanted Eye); End-Use (Hospitals End-Use, Outpatient Facilities End-Use, Research & Manufacturing End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 52 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â